Saturday 17 October 2026
Export TELO’s income statement to Excel — free account
Telomir Pharmaceuticals, Inc.
TELO Healthcare Biotechnology
In the quarter to June 2026, EPS fell 364.7% and free cash flow fell 45.3%, each against the same quarter a year earlier.
1.05
0.00
0.00%
Follow TELO
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (1,885.50%) | (384.26%) | (317.65%) | (301.57%) |
+8 more TTM periods Free account |
|
| (1,678.31%) | (293.73%) | (240.34%) | (265.05%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(1,032.88%) | (185.89%) | (176.09%) | (160.34%) | |
Free Cash Flow per Share |
(0.08) | (0.13) | (0.12) | (0.10) | |
Free Cash Flow |
(4.91) | (4.60) | (3.69) | (3.09) | |
| Other line items | |||||
Cash ROIC |
(47.53%) | (42.87%) | (27.94%) | (21.61%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(1,087.00) | (3,612.46) | — | — | |
Operating CF/Net income |
0.09 | 0.50 | 0.35 | 0.28 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.08) | (0.13) | (0.12) | (0.10) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates